HEC-169584 / Sunshine Biopharma - LARVOL DELTA

A Safety, Tolerability, Pharmacokinetics/Pharmacodynamics Study of HEC169584 Capsules in Healthy Subjects (clinicaltrials.gov) - P1 | N=96 | Recruiting | Sponsor: Sunshine Lake Pharma Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Hepatology

A Safety, Tolerability, Pharmacokinetics/Pharmacodynamics Study of HEC169584 Capsules in Healthy Subjects (clinicaltrials.gov) - P1 | N=96 | Not yet recruiting | Sponsor: Sunshine Lake Pharma Co., Ltd.

New P1 trial • Hepatology

Another breakthrough for domestically produced MASH new drug: HEC169584 of East Sunshine Pharmaceutical is about to start clinical trials! (Sohu.com) - "On December 16, 2024, East Sunshine Pharmaceutical was approved to conduct clinical trials of its new class of drugs HEC169584. This drug was developed by the company with the help of an artificial intelligence-driven small molecule drug design platform. The team used the HEC-GEN model to generate a wealth of candidate molecules and evaluated their affinity with the target protein."

New trial • Metabolic Dysfunction-Associated Steatohepatitis